PMC:7781431 / 34445-36506
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1058 | 11-58 | Species | denotes | Severe acute respiratory syndrome Coronavirus 2 | Tax:2697049 |
1059 | 60-70 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1060 | 84-95 | Species | denotes | coronavirus | Tax:11118 |
1061 | 218-231 | Species | denotes | Coronaviridae | Tax:11118 |
1062 | 298-308 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1063 | 115-139 | Disease | denotes | 2019 coronavirus disease | MESH:C000657245 |
1064 | 141-149 | Disease | denotes | COVID-19 | MESH:C000657245 |
1065 | 154-173 | Disease | denotes | respiratory disease | MESH:D012140 |
1066 | 199-207 | Disease | denotes | COVID-19 | MESH:C000657245 |
1067 | 359-365 | Disease | denotes | deaths | MESH:D003643 |
1091 | 1152-1183 | Gene | denotes | angiotensin-converting enzyme 2 | Gene:59272 |
1092 | 1185-1189 | Gene | denotes | ACE2 | Gene:59272 |
1093 | 1322-1327 | Gene | denotes | spike | Gene:43740568 |
1094 | 1329-1330 | Gene | denotes | S | Gene:43740568 |
1095 | 650-660 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1096 | 990-998 | Species | denotes | patients | Tax:9606 |
1097 | 1311-1321 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1098 | 1935-1945 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1099 | 598-602 | Chemical | denotes | PGE2 | MESH:D015232 |
1100 | 619-625 | Chemical | denotes | lipids | MESH:D008055 |
1101 | 683-699 | Chemical | denotes | arachidonic acid | MESH:D016718 |
1102 | 701-728 | Chemical | denotes | dihomo-gamma-linolenic acid | MESH:D015126 |
1103 | 734-754 | Chemical | denotes | gamma-linolenic acid | MESH:D017965 |
1104 | 1100-1109 | Chemical | denotes | Elovanoid | |
1105 | 1226-1232 | Chemical | denotes | lipids | MESH:D008055 |
1106 | 1398-1411 | Chemical | denotes | Elovanoid-N32 | |
1107 | 1676-1684 | Chemical | denotes | fish oil | MESH:D005395 |
1108 | 825-845 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
1109 | 891-900 | Disease | denotes | infection | MESH:D007239 |
1110 | 962-989 | Disease | denotes | deficiency of SPMs in obese | MESH:D009765 |
1111 | 1054-1074 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
1112 | 1621-1641 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
1113 | 1871-1892 | Disease | denotes | inflammatory diseases | MESH:D007249 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T42 | 396-411 | Phenotype | denotes | cytokine storms | http://purl.obolibrary.org/obo/HP_0033041 |
T43 | 661-675 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
T44 | 796-803 | Phenotype | denotes | Obesity | http://purl.obolibrary.org/obo/HP_0001513 |
T45 | 1486-1500 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T344 | 0-10 | Sentence | denotes | SARS-CoV-2 |
T345 | 11-297 | Sentence | denotes | Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) refers to a coronavirus strain that causes 2019 coronavirus disease (COVID-19), a respiratory disease that is the cause of the COVID-19 pandemic (Coronaviridae Study Group of the International Committee on Taxonomy of, 2020). |
T346 | 298-426 | Sentence | denotes | SARS-CoV-2 is an RNA virus that infects the lungs and causes deaths through complications such as cytokine storms (Goldin et al. |
T347 | 427-433 | Sentence | denotes | 2020). |
T348 | 434-612 | Sentence | denotes | The anti-inflammatory action of mesenchymal stem cells is well known, and it is believed that these mesenchymal stem cells exhibit anti-inflammatory action through PGE2 and LXA4. |
T349 | 613-795 | Sentence | denotes | These lipids mediators alleviate the SARS-CoV-2 cytokine storm, while arachidonic acid, dihomo-gamma-linolenic acid, and gamma-linolenic acid inactivate enveloped viruses (Das 2020). |
T350 | 796-930 | Sentence | denotes | Obesity is a risk factor for SARS-CoV-2 infection, and a BMI of 30 kg/m2 increases the risk of infection by 61% (Bello-Chavolla et al. |
T351 | 931-937 | Sentence | denotes | 2020). |
T352 | 938-1086 | Sentence | denotes | This is likely due to a deficiency of SPMs in obese patients, and this deficiency promotes adverse reactions during SARS-CoV-2 infection (Pal et al. |
T353 | 1087-1093 | Sentence | denotes | 2020). |
T354 | 1094-1219 | Sentence | denotes | LXA4, Elovanoid-N32 or RvD6 isomers reduced expression of angiotensin-converting enzyme 2 (ACE2), but NDP1 did not reduce it. |
T355 | 1220-1390 | Sentence | denotes | These lipids mediators also counteract the binding of the receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein to the injured cornea (Figs. 3 and 4) (Pham et al. |
T356 | 1391-1397 | Sentence | denotes | 2020). |
T357 | 1398-1523 | Sentence | denotes | Elovanoid-N32 or RvD6 isomers also attenuated the expression of cytokines involved in a cytokine storm and hyperinflammation. |
T358 | 1524-1754 | Sentence | denotes | Based on previous study results that have demonstrated SPMs as potential therapeutic targets for SARS-CoV-2 infection, studies and review on the use of fish oil, an SPMs precursor, as an adjuvant are in progress. (Torrinhas et al. |
T359 | 1755-1774 | Sentence | denotes | 2020; Rogero et al. |
T360 | 1775-1781 | Sentence | denotes | 2020). |
T361 | 1782-2054 | Sentence | denotes | SPMs and soluble epoxide hydrolase inhibitors are currently in clinical trials for other inflammatory diseases and can be quickly converted and used for SARS-CoV-2 management through the removal of cellular debris and inhibition of inflammatory cytokines (Panigrahy et al. |
T362 | 2055-2061 | Sentence | denotes | 2020). |